On July 23, 2025, the French biotech company Abivax announced highly positive Phase 3 results from two clinical trials evaluating the efficacy of its drug obefazimod for the treatment of ulcerative colitis (UC).
This innovative therapy targets microRNA miR-124 — a novel mechanism discovered through fundamental research by Professor Jamal Tazi’s team at IGMM (CNRS / University of Montpellier), in collaboration with the Abivax joint laboratory in Montpellier.
The announcement made headlines on the financial markets: Abivax’s stock surged by over 520%, an event reported in Le Monde.
